Fluorouracil Side Effects: Systemic vs. Topical Risks

Fluorouracil, often written as 5-FU, causes side effects that span nearly every organ system, from predictable problems like mouth sores and diarrhea to rarer but serious complications involving the heart and brain. How the drug is given, how fast your body breaks it down, and what other medications you take all shape which side effects hit hardest. Some are manageable nuisances; a few are medical emergencies with a dedicated antidote. Understanding the full landscape helps you know what to watch for, what to report immediately, and what your care team can do to reduce the burden.

The Gut Takes the Biggest Hit

The most common side effects of fluorouracil involve the digestive tract. Diarrhea, nausea, vomiting, and painful mouth sores (called mucositis or stomatitis) affect a large share of patients on systemic 5-FU. These happen because 5-FU targets rapidly dividing cells, and the lining of the mouth and intestines renews itself faster than almost any other tissue in the body. Research in animal models shows that 5-FU triggers a surge of inflammatory signaling molecules throughout the colon, while simultaneously reducing the expression of water-channel proteins that normally help the intestinal lining manage fluid balance.¹ The result is diarrhea driven by both inflammation and a breakdown in the gut’s ability to absorb water properly. At the cellular level, the inflammatory cascade promotes the death of enterocytes, the cells that line the intestinal wall.² Reactive oxygen species also play a role in damaging the intestinal lining and worsening diarrhea.³

Mucositis of the mouth can be particularly miserable, making it painful to eat, drink, or swallow. A straightforward and low-tech approach to prevention is oral cryotherapy: sucking on ice chips for roughly 30 minutes around the time of each 5-FU bolus infusion. Randomized studies have found that patients using cryotherapy had significantly less mouth soreness across multiple chemotherapy cycles compared to control groups, as judged by both the patients themselves and their doctors.⁴ The cold narrows blood vessels in the mouth lining, temporarily reducing the amount of drug delivered to those tissues during the infusion window. It costs nothing, has no side effects of its own, and does not interfere with the cancer-fighting action of the drug.⁵ It works best with bolus dosing schedules because the peak drug concentration in the blood is brief enough that the vasoconstriction from ice chips covers the critical window.

Hand-Foot Syndrome

One of the more distinctive skin reactions to fluorouracil is palmar-plantar erythrodysesthesia, commonly called hand-foot syndrome. It shows up as redness, swelling, tingling, and eventually painful peeling of the palms and soles. In early stages you might notice a burning or prickling sensation before any visible change appears.⁶ At its worst, the skin cracks and blisters enough to make walking or gripping objects difficult. The condition is thought to stem from damage to small blood vessels in the hands and feet, followed by an inflammatory response, possibly involving enzymes that metabolize the drug locally in those tissues.⁷

How you receive fluorouracil matters here. In a large analysis comparing bolus dosing (a quick push of drug) with continuous infusion (a slow drip over hours or days), hand-foot syndrome was far more common with continuous infusion, occurring in about 34% of patients compared to 13% with bolus dosing.⁸ On the flip side, serious blood-count drops were much more common with bolus dosing (about 31% versus 4%). So the two schedules trade off one toxicity for another, and your oncologist chooses based on the specific cancer, the treatment regimen, and your risk profile.

Drops in Blood Cell Counts

Fluorouracil suppresses the bone marrow’s ability to produce blood cells, which can lead to low white blood cells (raising infection risk), low red blood cells (anemia and fatigue), and low platelets (easier bleeding and bruising). Studies in animal models show that after a dose of 5-FU, the precursor cells for both platelet-forming cells and infection-fighting white blood cells drop sharply, reaching their lowest point within the first week.⁹ Platelet counts then rebound to well above normal levels for about a week before settling back down. White blood cells recover too, but without the same exaggerated overshoot.

The clinical takeaway is that your blood counts will typically be checked before each treatment cycle. If your white cell count drops too low, your oncologist may delay the next dose or reduce it. As noted above, the bolus dosing schedule carries a higher risk of severe blood-count suppression than continuous infusion does.¹⁰ Fever during a low white-cell-count period is a reason to contact your care team immediately, because infections can escalate fast when your immune defenses are depleted.

Cardiovascular Toxicity

Heart-related side effects from fluorouracil are less common than gut problems, but they can be dangerous and sometimes fatal. Reported rates vary widely, from roughly 1% to 30% depending on how the studies define “cardiovascular event” and how closely patients are monitored. The symptoms span a broad range: chest pain resembling angina, irregular heart rhythms, and in severe cases heart attack or cardiogenic shock.¹¹ Chest pain during or shortly after a 5-FU infusion should be treated as an urgent concern, not dismissed as anxiety or indigestion.

The exact reason fluorouracil harms the heart is not fully understood. Leading theories include spasm of the coronary arteries (temporarily choking off blood supply to heart muscle), direct damage to heart muscle cells through injury to their mitochondria, and dysfunction of the endothelial cells that line blood vessels.¹² People who already have coronary artery disease are thought to be at higher risk, though cardiotoxicity can occur even in patients with no prior heart history. If you experience chest tightness, shortness of breath, or a sudden change in heart rhythm during treatment, the infusion is usually stopped and cardiac monitoring initiated.

Neurological and Cognitive Effects

Neurological toxicity from 5-FU is uncommon, but when it occurs it can be alarming. Symptoms include confusion, slurred speech, difficulty walking, and altered behavior. In one documented case, a patient developed sudden confusion, cognitive disturbances, and paranoia 19 days after starting chemotherapy; brain imaging showed no structural damage, and the only notable lab finding was a mildly elevated ammonia level. Stopping the drug and treating with supportive care led to a full recovery within a week.¹³

The leading explanation for this neurotoxicity involves ammonia buildup. A breakdown product of 5-FU interferes with a step in cellular energy metabolism, causing ammonia to accumulate in the blood and cross into the brain.¹⁴ In more severe cases, brain MRI can reveal characteristic swelling in the deep white matter and the corpus callosum, a pattern called toxic leukoencephalopathy. These changes reflect swelling inside the myelin sheaths that insulate nerve fibers. The good news is that the condition is usually reversible once 5-FU is stopped, though recovery can take days to weeks.

Separate from these acute neurological events, there is growing awareness of longer-term cognitive effects, sometimes called “chemobrain” or “chemofog.” Fluorouracil can cross the blood-brain barrier and appears to be directly toxic to certain brain cells, including progenitor cells and the oligodendrocytes responsible for producing myelin.¹⁵ Research in animal models has confirmed that 5-FU damages myelin integrity and is associated with deficits in memory-related brain regions.¹⁶ Patients may notice trouble with concentration, short-term memory, or mental sharpness that persists after treatment ends. This is not the same thing as the acute encephalopathy described above; it is subtler, develops gradually, and can linger for months or longer.

Eye Problems That Often Go Unrecognized

One underappreciated side effect of systemic fluorouracil is excessive tearing and irritation of the eyes. The drug is secreted in tears, where it irritates the lining of the tear ducts and can cause scarring and narrowing over time. One early study estimated that about 30% of patients on 5-FU develop some degree of irritation of the tear drainage system.¹⁷ Later case reviews have noted that obstruction of the tear ducts after systemic fluorouracil is more frequent than commonly assumed.¹⁸

In practice, many patients chalk up watery eyes to allergies or dry air and never mention it to their oncologist. But if the tear duct narrows or scars shut, the tearing becomes chronic and the blockage may eventually require a minor surgical procedure to correct. If your eyes start watering persistently during 5-FU treatment, it is worth bringing up early rather than waiting for the ducts to scar.

Genetic Vulnerability and DPD Deficiency

Your body relies on an enzyme called dihydropyrimidine dehydrogenase (DPD) to break down fluorouracil. People with inherited variants that reduce DPD activity clear the drug much more slowly, which means normal doses can produce drug levels several times higher than expected. A meta-analysis found that patients carrying certain DPD gene variants had roughly two and a half times the risk of severe 5-FU toxicity.¹⁹ Individual variants can push the odds even higher. One study found that a single DPD gene variant had an odds ratio above four for developing toxicity, meaning carriers were roughly four times more likely to experience serious side effects than non-carriers.²⁰

In some countries, pre-treatment testing for DPD deficiency is now recommended or required before starting fluorouracil-based regimens. A complete absence of DPD activity is rare, but partial deficiency is more common than many people realize. When identified in advance, doses can be reduced or an alternative drug chosen, potentially avoiding a life-threatening reaction. If you are about to start 5-FU or its oral cousin capecitabine, asking about DPD testing is a reasonable conversation to have with your oncologist.

Topical Fluorouracil Is a Different Story

Fluorouracil also comes as a cream used to treat precancerous skin patches and certain superficial skin cancers. The side-effect profile for topical use is far narrower than for systemic chemotherapy. Redness, crusting, and soreness at the application site are expected and even desirable, because they indicate the drug is killing abnormal cells. These reactions are limited to the treated skin. Studies have confirmed that fluorouracil cream is only minimally absorbed into the bloodstream, with urinary measurements of drug levels extremely low even in patients using the stronger 5% formulation.²¹

A question that sometimes comes up for dermatology patients is whether carrying a DPD gene variant means topical fluorouracil is also dangerous. A study specifically examining this found no cases of grade 3 or higher toxicity in any patient, including those carrying DPD variants. All reactions were grade 1 or 2 skin-level effects, and while DPD variant carriers had a nominally higher rate of local skin irritation, the difference was not statistically significant.²² For most patients, topical fluorouracil is safe even with a DPD variant, though individual decisions should still involve your prescriber.

A Dangerous Drug Interaction Worth Knowing About

One of the most dramatic drug interaction stories in pharmacology involves fluorouracil and an antiviral drug called sorivudine, which was used to treat shingles. In the 1990s in Japan, 15 patients died after taking sorivudine alongside an oral fluorouracil-type drug. Investigation showed that sorivudine’s breakdown product irreversibly shut down DPD, the same enzyme that people with inherited deficiency lack.²³ With DPD knocked out, 5-FU levels in the body skyrocketed, producing lethal toxicity.²⁴ Sorivudine was subsequently pulled from the market, and the case became a textbook example of why drug-interaction screening around fluoropyrimidines needs to be thorough. Any medication or supplement that affects DPD activity could theoretically amplify 5-FU toxicity, which is why your oncology team will review your full medication list before treatment.

The Emergency Antidote

When fluorouracil toxicity becomes life-threatening, whether from an overdose, a dosing error, or an unexpectedly severe reaction due to DPD deficiency, there is a specific antidote: uridine triacetate, an oral medication approved by the FDA in 2015. It works by flooding the body with uridine, which competes with the toxic fluorouracil byproducts for incorporation into cells. In a large emergency-use dataset, 96% of overdose patients treated with uridine triacetate survived, with rapid reversal of severe cardiac and neurological toxicity and prevention or resolution of mouth sores and low blood counts.²⁵ Before uridine triacetate existed, the survival rate in such cases was estimated at only about 16%.²⁶

Timing matters. Animal studies and clinical experience both show that starting uridine triacetate within 24 hours of the fluorouracil exposure provides the strongest protection. Effectiveness declines the longer treatment is delayed, and after about 96 to 120 hours the benefit drops substantially.²⁷ That said, case reports have described improvement even when the antidote was given well beyond 120 hours, so late treatment may still be worth attempting in severe situations.²⁸ The drug itself is well tolerated, with nausea and vomiting being the main complaints.

Reproductive and Fertility Concerns

Fluorouracil poses real risks to reproductive health and to a developing fetus. In both animal and human data, the drug is associated with developmental abnormalities, damage to ovarian tissue, and disruption of sperm production. In males, 5-FU alters the structure of reproductive organs, shifts hormone levels, and impairs the process that produces sperm, ultimately reducing sperm counts. In females, it can damage growing ovarian follicles and is linked to menstrual irregularities.²⁹

One piece of relatively encouraging news comes from animal research showing that while 5-FU devastates the actively growing follicles in the ovary, the dormant primordial follicles that represent the long-term reserve appear to survive. This suggests that 5-FU is unlikely to cause permanent infertility in women of reproductive age, because the ovarian reserve itself is not depleted, even though fertility may be temporarily impaired during and after treatment.³⁰ Nonetheless, effective contraception during treatment and for a period afterward is standard practice, given the drug’s known ability to harm developing embryos. Fertility preservation conversations should ideally happen before treatment starts.

How the Many Toxicities Connect

At its core, fluorouracil does not target cancer exclusively. It disrupts DNA synthesis and RNA processing in all rapidly dividing cells, which is why the side-effect list reads like a tour of every tissue in the body that turns over quickly: the gut lining, the bone marrow, the skin of the hands and feet, the mucous membranes. The cardiovascular, neurological, and eye effects add additional layers because the drug also causes oxidative stress, endothelial damage, and inflammation in tissues that are not rapidly dividing.³¹ The range is broad enough that oncologists monitor patients across multiple fronts simultaneously: blood work before each cycle, cardiac symptoms during infusion, skin and neurological checks throughout, and eye complaints at any point.

For patients, the practical implication is that almost any new symptom during 5-FU treatment deserves a phone call to your care team, even if it seems unrelated to cancer or chemotherapy. Watery eyes, tingling hands, chest tightness, sudden confusion, persistent diarrhea: each of these could be a fluorouracil side effect, and several of them benefit from early intervention. The existence of an effective antidote for severe cases makes rapid recognition and reporting even more valuable, because the window for the best outcome is measured in hours, not days.